
via SlideShare
A new approach to killing C. difficile that silences key bacterial genes while sparing other bacteria may provide a new way to treat the most common hospital-acquired bacterial infection in the United States, according to researchers.
While conventional antibiotics treat bacterial infections, they can also cause a condition in the colon called C. difficile infection, due to the drug killing both good and bad bacteria in the gut.
In a lab, researchers created three new antibiotics that kill C. difficile by preventing the expression of bacterial genes that are important for its survival. This approach — called antisense therapy — allows the drug to kill only C. difficile, unlike many antibiotics that kill multiple forms of bacteria.
“We were able to show that these drugs can zero in on and kill C. difficile bacteria while leaving other bacteria alone,” said Arun Sharma, associate professor of pharmacology, Penn State College of Medicine. “We’re still working to refine these drugs and make them even better, with the eventual goal of testing them clinically.”
David Stewart, an associate professor of surgery at the University of Arizona who along with Sharma is a co-principal investigator on this study, said the drug works in a completely different manner than the antibiotics currently used.
“These drugs are organism specific, meaning that they target only one kind of bacteria, kind of like smart antibiotics,” Stewart said. “They’re precise. And that’s especially important with C. difficile infections because this bacteria is uniquely, selectively advantaged to exploit ecological disturbances in the human gut.”
While C. difficile is normally present in the gut, other “good” bacteria are also present, and all these bacteria contribute to a person’s microbiome. When a person’s microbiome is healthy and balanced, it keeps bad bacteria like C. difficile under control.
But if a patient takes an antibiotic for another condition, the antibiotic kills many different types of bacteria, including the good ones keeping C. difficile under control. This allows C. difficile to thrive, causing an infection that can result in severe gastrointestinal symptoms. Since antibiotics can contribute to C. difficile infections, the researchers said a new, alternative treatment for these infections is desirable.
“Ideally, a treatment for C. difficile would have no effect on other bacteria,” Stewart said.
The researchers, who recently published their findings in the Journal of Antibiotics, said that while most antibiotics lack organismal specificity — the ability to target just one type of organism — antisense treatments show great potential for being able to target only specific bacteria.
“Our antisense antibiotics contain genetic material which is complementary to bacterial genetic material, so we designed our genetic material to target specific genes in C. difficile,” Stewart said. “And when our genetic material binds to the bacterial genetic material, it prevents the expression of bacterial genes. And that can cause C. difficile to die.”
The drug tested in the study consisted of two components: the antisense compound that targeted the genetic material in C. difficile — referred to as an antisense oligonucleotide (ASO) — and a carrier compound that transported the ASO into the bacteria, referred to by the research team as a CAB. The researchers tested three versions of the drug, each with a different version of CAB.
The researchers tested each compound to see how much of the drug was required to kill C. difficile bacteria, whether it was toxic or not to human colon cells, and whether it also harmed other bacteria normally found in the gut — like E. coli.
“Ultimately, we wanted these compounds to deliver the drug into the C. difficile bacteria without hurting other bacteria or the patient,” Sharma said. “After testing these three, we found that one carrier in particular — CYDE-21 — was the best at delivering an effective dose of the drug into the bacteria.”
In the future, the researchers said they will conduct further studies to continue to refine the carriers to increase their capacity and minimize their effect on other bacteria and human cells.
“In this study, as a first effort, the carrier is pretty good, and we’d like to do even better,” Stewart said. “It has minimal antibacterial activity, minimal toxicity and it’s an effective carrier of our cargo. So what we’re working on now is modifying our carriers for future testing in preparation for animal studies.”
Learn more: Killing bacteria by silencing genes may be alternative to antibiotics
The Latest on: Antisense therapy
[google_news title=”” keyword=”antisense therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Antisense therapy
- Morgan Stanley Maintains Ionis Pharmaceuticals (IONS) Equal-Weight Recommendationon September 27, 2023 at 3:34 pm
Fintel reports that on September 27, 2023, Morgan Stanley maintained coverage of Ionis Pharmaceuticals (NASDAQ:IONS) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 9.39% Upside ...
- Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challengeson September 27, 2023 at 10:12 am
William Blair writes that Ionis continues to expand its partnered portfolio, generating nondilutive funds to support the growth and development of its wholly-owned pipeline and reiterates its ...
- Ionis Posts Trial Data in Rare Disease That Position It to Finally Set Out on Its Ownon September 26, 2023 at 8:43 pm
FCS has no FDA-approved therapies, but Carlsbad, California-based Ionis aims to bring patients the first one. Ionis specializes in antisense oligonucleotide drugs, genetic medicines that bind to ...
- Oligonucleotides News and Researchon September 24, 2023 at 5:00 pm
An antisense therapy developed by Joel D. Richter, PhD, Sneha Shah, PhD, and Jonathan K. Watts, PhD, at UMass Chan Medical School and Elizabeth Berry-Kravis, MD, PhD, at RUSH University Medical ...
- Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemiaon September 20, 2023 at 5:00 pm
Patients who were not receiving triglyceride-lowering therapy were considered eligible ... a second-generation antisense drug, produced dose-dependent mean reductions of 80% in APOC3 levels ...
- Antisense & RNAi Therapeutics Market Set to Double to $2.13 Billion by 2032, Driven by Strong 6% CAGR Growthon September 19, 2023 at 4:45 am
Antisense therapy, a form of gene therapy, specifically targets and halts the production of disease-causing proteins by binding to the messenger RNA (mRNA) molecules necessary for their synthesis.
- Autism Newson September 17, 2023 at 5:00 pm
Specifically, their sensor ... July 5, 2023 — An antisense therapy restores production of the protein FMRP in cell samples taken from patients with fragile X syndrome. This breakthrough was ...
- New insights into melanoma development and therapyon September 13, 2023 at 6:19 pm
Researchers have revealed that the expression of a specific isoform of GREB1 Is4 is induced in malignant melanoma cells by the melanocyte-specific transcription factor, MITF. They revealed that GREB1 ...
- Utility of Antisense Oligonucleotides (ASOs) in Next-Generation Biotherapeuticson September 7, 2023 at 2:00 pm
Antisense technology employs short ... (The drug was withdrawn in 2001; introduction of HAART antiviral therapy reduced the incidence of AIDS CMV retinitis and Fomivirsen was no longer needed.) ...
via Bing News